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Abstract
Prescription drug abuse is the fastest growing drug problem
in America. Among the different prescription drugs being
abused, analgesics are the most commonly abused group of
drugs. In the last few years, there is increasing evidence of
abuse of tramadol, which is an atypical, centrally acting
opioid analgesic. The increasing abuse of tramadol has
prompted regulatory authorities to strengthen the product
labeling of tramadol with respect to its abuse potential. Furthermore, several states have added tramadol to their controlled substances list. In this article, we will review the
pharmacology of tramadol and some of the preclinical and
clinical studies that support its abuse liability. In addition, we
will focus on the risk factors that may predispose individuals
to tramadol abuse and the consequences of tramadol abuse
such as tramadol poisoning and tramadol dependence.
Lastly, potential strategies with an emphasis on the role of
the pharmacist and other health care professionals in controlling tramadol abuse will be discussed.
Introduction
Prescription drug abuse is defined as the use of a medication
for purposes outside of its original intention.1 Examples of
misuse include abusing a medication without a prescription,
using a medication in ways other than prescribed or intending to misuse the medicine for an "experience" or a "feeling." 1
Prescription drug abuse is the fastest growing problem in the
United States with approximately 6,600 new abusers each
day.2 Importantly, the problem affects the country as a whole
due to the large societal costs associated with it. The societal
cost of prescription drug abuse, including costs to health
care, the criminal justice system and lost workplace productivity, was estimated to be $55.7 billion in 2007. 2 Prescription drugs commonly abused include analgesics (pain relievers), tranquilizers, stimulants and sedatives.1 Among these
drugs, analgesics are the most commonly abused prescription drug category. In 2010, 12 million Americans 12 years of
age and older reported using prescription analgesics for
nonmedical uses for the first time. 2

Included in this category of prescription analgesics is
tramadol (Ultram®).1 Tramadol, approved in the United
States in 1995, is a nonscheduled analgesic indicated for the
treatment of moderate to moderately-severe pain. 3 For several years after its approval, tramadol was advocated as a
unique drug due to its supposed weak narcotic effects.3
These weak narcotic effects were initially seen as an advantage, as it was thought the drug could be safely used to treat
pain in patients with a history of narcotic abuse.3 However,
due to increased reports of overdose and suicides, product
labeling of tramadol was revised in July 2010.4 Revisions included warnings of an increased suicide risk for patients using tranquilizers or antidepressants and patients at risk for

addiction. 4 The labeling changes also emphasized the risks of
overdose and the abuse potential of the drug.4
Despite these warnings, tramadol continued to be widely
prescribed. In 2012, 29.8 million prescriptions of tramadol
were dispensed.3 Importantly, there has been increasing evidence of tramadol overdose and abuse.3 In 2011, poison control centers reported 12,424 cases of tramadol overdose,
with 6,361 of these exposures leading to death.3 In addition
to overdose, the 2011 National Survey on Drug Use and
Health reported that 2.6 million people ages 12 and older
used tramadol for nonmedical uses in the past year, with the
most commonly abused dosage form being oral.3.s In 2013,
the Drug Enforcement Administration (DEA) challenged the
previous classification of tramadol3 and stated in its report
that, "Dependence and abuse, including drug seeking behavior and taking illicit actions to obtain tramadol are not limited to those patients with prior history of opioid dependence."3 Furthermore, several states, including Arkansas, Kentucky and, most recently, New York, have included tramadol
on their controlled substances lists.6.7 In this review, we will
discuss the pharmacology of tramadol and the underlying
neural mechanism which facilitates tramadol abuse. We will
also explore the factors that increase the risk for tramadol
abuse and poisoning, as well as the treatment of tramadol
poisoning and withdrawal. Lastly, we will discuss strategies
to prevent tramadol abuse.
General Pharmacology
Tramadol is a centrally acting analgesic and is available as
both oral immediate-release formulations (50 mg in either
capsules, drops, tablets or soluble tablets) and sustainedrelease tablets. All formulations have a high bioavailability.
The plasma protein binding of tramadol is approximately 20
percents Tramadol is metabolized mainly by hepatic cytochrome P450 isoenzymes 206 and 3A4.B,9 Cytochrome P450
isoenzyme 2D6 (CYP2D6) is primarily responsible for the
metabolism oftramadol to its active metabolite O-desmethyltramadol.B,9,10-12 When CYP2D6 concentrations are low or
0-demethylation is inhibited, isoenzymes 2B6 and 3A4
(CYP2B6 and CYP3A4) contribute to metabolism of tramadol
into N-desmethyl-tramadol.B,9,11 Tramadol is excreted via the
kidneys and the elimination half-life is approximately six to
eight hours.B,9

Structurally, tramadol is similar to codeine and morphine.s.11
It is formulated as a racemic mixture of two enantiomers in
its parent form: (+)-tramadol and (-)-tramadol, which play
complementary and synergistic roles in mediating its analgesic effects.s.11 (+)-Tramadol inhibits reuptake of serotonin
and (-)-tramadol inhibits the reuptake of norepinephrine. In
addition, (+)-tramadol and its active metabolite, (+)-0desmethyl-tramadol, are mu opioid receptor agonists, which
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further enhance the analgesic efficacy of tramadoJ.0.11 Because of this dual mechanism of action, tramadol is classified
as an atypical opioid analgesic. However, despite this dual
mechanism of action, the analgesic potency of tramadol is
only about 10 percent that of morphine, a potent mu opioid
receptor agonist.8
The activation of mu opioid receptors by tramadol and its
active metabolite 0-desmethyl-tramadol play an important
role in the abuse liability of tramadoJ.B-n In humans, activation of mu opioid receptors results in positive reinforcement
and rewarding effects such as euphoria, relaxation and
drowsiness. Relaxation and drowsiness can be reinforcing
especially in individuals suffering from pain. These positive
reinforcing effects thus provide the major motivation for
continued use and subsequent abuse of tramadol. When
comparing tramadol and its metabolite 0-desmethyltramadol, the latter is a more potent agonist of the mu opioid
receptor. Therefore, both the reinforcing and analgesic effects of tramadol are more dependent on its conversion to its
active metabolite. Polymorphisms associated with the
CYP450 enzyme CYP2D6 greatly influence the effects of
tramadol. Based on the activity of CYP2D6, individuals can be
classified as poor metabolizers, normal metabolizers and
ultra-rapid metabolizers.io.12 Poor metabolizers have reduced or absent activity of CYP2D6 and the analgesic efficacy
of tramadol is decreased in these patients as compared to
those who have normal CYP2D6 activity.10.12 In contrast, ultra-rapid metabolizers of tramadol, who have increased activity of CYP2D6 and rapidly convert tramadol to its active
metabolite, are at a higher risk of abusing tramadol. Consistent with this hypothesis, higher rates of tramadol abuse
have been reported in individuals from Middle Eastern countries who are commonly ultra-rapid metabolizers of
tramado1.10.13

Drug Abuse Potential: Evidence from Clinical and
Preclinical Studies
Preclinically, the positive reinforcing effects of drugs can be
assessed using the conditioned place preference (CPP)
model.H Conditioned place preference is conducted using an
apparatus that has two chambers, which are distinct with
respect to their texture and/or color. The drug of interest is
administered to the animal and the animal is placed in one of
the chambers. This pairing of the drug to a particular chamber is done repeatedly over several days. This process is
known as conditioning and allows the animals to associate
the reinforcing effects of the drug (if any) with the specific
environment. Along with this pairing of the drug to one of the
chambers, the animal is also conditioned to a distinct chamber in the apparatus using a vehicle (control). On the test
day, the animal is allowed to explore both the drug- and vehicle-associated chambers in a drug-free state. The time spent
by the animal in the drug-associated compartment is compared to the time spent by the animal in the vehicleassociated compartment. If a drug is reinforcing, the animal
will spend significantly more time in the drug-associated
compartment compared to the vehicle-associated compartment.14 Several preclinical studies showed that tramadoladministration induced CPP in rats.15,l6 Additionally, tramadol
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enhanced morphine-induced CPP. Importantly, pretreatment
with mu receptor antagonist naloxone attenuated tramadolinduced CPP. Together these data suggest that tramadol has
positive reinforcing effects, which are mediated by the mu
opioid receptor. Furthermore, drugs with high abuse liability
increase the activity of the mesolimbic dopaminergic neurons in the brain. These mesolimbic dopaminergic neurons
originate in the ventral tegmental area in the midbrain and
project to several limbic sites including the nucleus accumbens (NAcc). The increase in activity of these mesolimbic
dopaminergic neurons is determined by measuring the increase in levels of the neurotransmitter dopamine in the
NAcc using a procedure called in vivo microdialysis.
Tramadol administration in rats increased NAcc dopamine
levels.1s In summary, these preclinical studies suggest that
tramadol has positive reinforcing effects and support the
abuse liability of tramadol.

Clinical Studies
A within-subject, randomized, double-blind, placebo-controlled
study evaluated the reinforcing effects of different doses of
tramadol (200 and 400 mg), oxycodone (20 and 40 mg) and
codeine (100 and 200 mg) by allowing subjects to selfadminister the different drugs and placebo. The highest selfadministration was observed when subjects received the 400
mg tramadol compared to 200 mg of tramadol, placebo and
both doses of oxycodone and codeine. The high rates of selfadministration suggest that 400 mg of tramadol has strong
reinforcing effects. In addition, the study also reported that
400 mg of tramadol increased mu opioid receptor agonistlike measures such as itchy skin and pupillary constriction.
Lastly, the study reported that all drugs (except low doses of
codeine) increased subjective measures of abuse liability
such as "liking" or "high" for the drug. Taken together, these
data suggested that tramadol has a high abuse potential.17
Several other clinical studies also reported findings that support the abuse potential of tramadoJ.8.11.13,1s.1?
In contrast to the above studies, some clinical studies conducted immediately after the approval of tramadol reported
that tramadol may not have abuse potentiaJ.16 It is not entirely clear why these studies suggested that tramadol is not
linked with the possibility of abuse. One possible reason
could be that these studies were conducted in individuals
with a history of opioid drug abuse, who generally develop
tolerance to the reinforcing effects of weaker reinforcers.
The relatively weak reinforcing effects of tramadol were,
therefore, not detected in these subjects. Another possible
reason could be that in most of these studies, tramadol was
administered intramuscularly rather than orally. As described above, the active metabolite of tramadol is mainly
responsible for its reinforcing effects. The conversion of
tramadol to this specific active metabolite is maximal when it
is administered orally, due to hepatic first pass effect via CYP
isoenzymes. The results of the studies described above contributed to the misguided perception of low abuse potential
of tramadol, and to its continued use and abuse.1.4

Tramadol Abuse and Overdose
One potentially fatal consequence of tramadol abuse is
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tramadol overdose and poisoning. A review of 114 studies of
tramadol-intoxicated subjects suggests that 80 percent of the
patients poisoned themselves with the intent of suicide.s
These data therefore suggest that physicians and pharmacists must be very careful in prescribing tramadol for patients with a history of suicidal ideation, previous suicide
attempts or depression. Furthermore, patients suffering from
depression are at an increased risk of tramadol poisoning.
Clinical reports suggest that there is extensive comorbidity in
patients suffering from depression and pain.ls Patients with
chronic pain have decreased serotonin and tryptophan concentrations in the hippocampus, which may predispose them
to depression. 18 In addition, depressed patients may be more
likely to develop chronic pain due to an alteration in the utilization of tryptophan.10 It is logical to recognize that some
patients on tramadol, who may also have chronic pain, may
be diagnosed with, or be at an increased risk for, depression.
Furthermore, taking tramadol concomitantly with a benzodiazepine (a class of drugs used to treat central nervous
system (CNS) disorders, including depression) predisposes
individuals to cardiopulmonary arrest.5 The pharmacodynamic interaction of tramadol and a comorbid psychiatric
disorder, like depression, along with the pharmacokinetic
interactions between tramadol and depression medications
may predispose individuals to tramadol poisoning. In addition to depression medications, risk of tramadol poisoning is
increased following concomitant administration of tramadol
with other CNS-depressant medications/substances including alcohol, tranquilizers, sedatives and muscle relaxants.4,19
In summary, patient groups prone to tramadol-related poisonings and deaths include patients with a previous history
of depression or suicidal ideation and attempts as well as a
history of misuse of alcohol and other CNS-depressant medications.
Patients who have abused or intentionally overdosed on
tramadol may present with adverse effects such as nausea,
vomiting, central nervous system depression, tachycardia,
seizures and apnea. Some patients may present with symptoms characteristic to serotonin syndrome, which include
altered mental state, neuromuscular hyperactivity and autonomic dysfunction.s.20. 21 Management of tramadol poisoning
involves treatment of symptoms of overdose as they arise
and providing supportive care to ensure patient comfort and
safety.22 Naloxone, an opioid antagonist, is used as an antidote to treat tramadol poisoning.23 However, a much larger
dose of naloxone is required for tramadol poisoning in comparison to the dose needed to treat poisoning of other
opioids.23 However, the use of naloxone as an antidote to
treat tramadol poisoning is controversial as an increased risk
of seizures has been reported with its use. 23

Tramadol Withdrawal and Treatment
Another major problem with tramadol abuse is tramadol
dependence. In tramadol-dependent patients, withdrawal
from tramadol results in symptoms such as abdominal
cramps, anxiety, bone pain, diarrhea, goose flesh, insomnia,
lacrimation, nausea, restlessness, rhinorrhea and sweating.2 4
These withdrawal symptoms are similar to those seen in
opioid dependent patients. Some patients report atypical

withdrawal symptoms including severe anxiety, panic
attacks, unusual CNS symptoms, sensory symptoms and hallucinations.24 These latter symptoms are similar to those observed in patients who withdraw from selective serotonin
reuptake inhibitors (SSRis).24 This parallel may be due to the
ability of tramadol to block the reuptake of serotonin, similar
to SSRls. 24
Treatment of tramadol withdrawal is patient specific. In most
cases, a gradual reduction of the patient's tramadol dose,
rather than stopping suddenly, yields the least withdrawal
symptoms.25 Unfortunately, there is no standardized protocol for reducing tramadol administration; patients should
work with their doctor and pharmacist to set a schedule that
works for them.25Tramadol withdrawal symptoms are generally managed through supportive care in a way that is most
comforting to the patient. 25 Treatment of these symptoms
is critical as the symptoms can lead to relapse among abstinent tramadol-dependent patients. 2s
In addition to treatment of the withdrawal symptoms, it is
necessary to address any underlying factors that may have
facilitated tramadol abuse. For example, if the patient continues to experience pain and needs an analgesic, switching to a
nonopioid analgesic may be an option.26 If that is not possible, another option would be the creation of a detailed monitoring strategy, in which both prescribers and pharmacists
are deeply involved, in order to ensure that the therapeutic
effects of tramadol outweigh negative consequences. This
may include extensive laboratory testing of the cardiovascular, pulmonary and central nervous systems for objective
data, as well as meeting with the patient to gain subjective
data. Due to the possible link between tramadol abuse and
depression, as discussed above, pharmacological treatment
of depressive symptoms may help facilitate the reduction of
tramadol abuse and prevent relapse in dependent patients.
In addition to this pharmacological treatment, psychological
support in the form of psychotherapy and support groups
may help prevent relapse in abstinent tramadol-dependent
patients.26

Prevention of Tramadol Abuse and Poisoning
Counseling and educating the patient is the first step to preventing tramadol abuse. Both prescribers and pharmacists
have a duty to educate patients on tramadol toxicity, overdose and abuse potential, as well as a duty to formulate
abuse prevention and treatment strategies individualized to
each patient.
The use of multiple physicians and pharmacies by patients
often makes it difficult for a health care professional to know
every medication the patient is taking and the effects of each
of these medications. One way to prevent toxic effects and
fatalities in patients using tramadol, or any other opioid, is
monitoring what drugs are being prescribed, dispensed and
administered by one or more doctors using medication lists
and patient profiles. Medication lists and patient profiles allow the pharmacist to identify potentially harmful and fatal
drug interactions before they occur. For example, patient
profiles increase pharmacists' ability to see if a patient taking
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a CNS depressant prescribed by one doctor is prescribed
tramadol by a different or the same doctor. Furthermore, it
gives pharmacists an opportunity to discuss with prescribers
possible alternatives to tramadol and/or other interacting
medications. Thus, pharmacists have the unique ability to
catch and rectify a problem before it occurs.
As stated previously, there is evidence of increased tramadol
abuse in certain groups of patients, such as those with a previous or current history of emotional disturbances, depression, suicidal ideation, suicidal attempts, as well as previous
or current use of tranquilizers, alcohol and other CNS-active
drug abuse. Therefore, another useful approach to decrease
tramadol abuse would be to screen such patients after careful review of their medical histories. In these patients, it may
be necessary to either avoid prescribing tramadol or prescribe tramadol with careful and rigorous monitoring as described above. Additionally, ultra-rapid metabolizers of
tramadol may be at greater risk for tramadol abuse compared to poor and normal metabolizers of tramadol. Thus, in
the current era of personalized medicine, it may be possible
to identify patients who may be at greater risk of tramadol
abuse based on CYP2D6 polymorphisms. Although no such
test currently exists, it is not inconceivable that such a test
may be developed in the near future. The test may perhaps
only require a simple cheek swab from a potential patient.
Regardless of the challenges, it is critical for every health
care professional to be alert to identify and prevent tramadol
abuse among the different patient populations.
Regulatory mechanisms can also help in reducing and preventing tramadol abuse. The use of automated prescription
reporting systems such as the Ohio Automated Rx Reporting
System (OARRS) can also play an important role in controlling prescription drug abuse. The OARRS requires outpatient
pharmacies to report every dispensed prescription of controlled substances, tramadol and carisoprodol. Because
tramadol prescriptions have to be reported to OARRS, and
because tramadol either is currently or is anticipated to be a
controlled substance in many states, pharmacists have the
ability to track patients' tramadol use, as well as the use of
any other opioids that may increase tramadol abuse and poisoning. Additionally, OARRS provides pharmacists the opportunity to cut down on inappropriate opioid use and to work
with prescribers and patients to find an alternate therapy.
However, OARRS is not a perfect system. One major limitation is the system's dependence on the compliance of pharmacies. If pharmacies are not properly reporting each
tramadol prescription within eight days of dispensing, as
required by OARRS, the system cannot work to its full potential. Although OARRS generates a report identifying pharmacies which have "failed to report" in an eight-day period, it
may not necessarily be a comprehensive list to identify all
errant pharmacies. Furthermore, as with almost any rule,
there are exceptions to reporting to OARRS. For example,
inpatient pharmacies, including federal Veterans Affairs (VA)
hospitals and nursing homes, as well as doctors who dispense out of their office, are not required to report to OARRS,
making the system less reliable.2 7,2a While there are flaws in
how tramadol use is monitored, important measures are be-
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ing taken to rectify the deficiencies. The effort on part of
some states (such as Arkansas, Kentucky and New York) to
make tramadol a controlled substance is a welcome step and
will help greatly in controlling the menace of tramadol drug
abuse.
Conclusion
The abuse of prescription analgesics like tramadol is a growing problem in the United States. In fact, the number of
tramadol poisoning cases over the last few years has increased despite improvements in label warnings. Tramadol
abuse can be confronted through patient education, increased regulatory surveillance and identifying patient
groups who may be predisposed to tramadol abuse/
poisoning. In addition, increasing awareness among physicians and pharmacists regarding the high abuse potential of
tramadol is warranted. This awareness, along with the resources described above (such as OARRS, medication lists
and patient profiles), will allow pharmacists and prescribers
to flag potential abuse before it occurs and step in with alternative therapies. As for patients who are already abusing
tramadol or have experienced tramadol poisoning, management strategies for both toxicity and withdrawal symptoms
are available in order to prevent further abuse and relapse.
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